imagine if JF decides to take the drug all the way through phase 3 swiftly and directly apply for FDA approval. I don’t see any concerns with fast track approval due to salvage therapy and reduced side effects. Such a shame that the future funds does not invest/buy out promising Australian companies, unlike the Singaporean sovereign funds: Temasek and GIC. I don’t even want to imagine the amount of cash generated by one of these DEP drug each year, would be multiple of the current SPL market CAP.
ALL the potential wasted because we are stuck with JF, also I don’t know why she is also the sole inventor of some Patents from SPL. Surely she doesn’t work in the lab? How could she be the sole inventor of any IP? Does someone know anyone working in SPL? I would love to hear their opinion on their CEO
Ann: DEP docetaxel and gemcitabine combination trial commences, page-17
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |